Tags

Type your tag names separated by a space and hit enter

Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
Virology. 2020 12; 551:26-35.V

Abstract

BACKGROUND

SARS-CoV-2 is a novel coronavirus and the cause of COVID-19. More than 80% of COVID-19 patients exhibit mild or moderate symptoms. In this study, we investigated the dynamics of viral load and antibodies against SARS-CoV-2 in a longitudinal cohort of COVID-19 patients with severe and mild/moderate diseases.

METHODS

Demographic and clinical information were obtained. Serial samples of blood, nasal and pharyngeal and anal swabs were collected at different time points post-onset. SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies were measured by qRT-PCR and immunoassays, respectively.

RESULTS

Respiratory SARS-CoV-2 RNA was detectable in 58.0% (58/100) COVID-19 patients upon admission and lasted for a median of 13 days post-onset. In addition, 5.9% (1/17) and 20.2% (19/94) of the blood and anal swab specimens were positive for SARS-CoV-2 RNA, respectively. Anal viral RNA was more frequently detected in the patients who were positive for viral RNA in the respiratory samples upon admission. Specific anti-SARS-CoV-2 antibody developed within two weeks after onset, reached peak approximately 17 days post-onset and then maintained at relatively high level up to 50 days we analyzed in most patients. However, the levels of antibodies were variable among the patients. High titers of antibodies appeared to be associated with the severity of the disease. Furthermore, viral proteins from different sources showed significant difference of serological sensitivity especially during the first week post-onset.

CONCLUSIONS

Our results indicate rapid clearance or self-elimination of viral RNA in about half of the COVID-19 patients upon admission. Viral RNA shedding of SARS-CoV-2 occurred in multiple tissues including the respiratory system, blood, and intestine. Variable levels of specific anti-SARS-CoV-2 antibody may be associated with disease severity. These findings have shed light on viral kinetics and antibody response in COVID-19 patients and provide scientific evidence for infection control and patient management.

Authors+Show Affiliations

Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China; Hospital of Dermatology, Southern Medical University, Guangzhou, China. Electronic address: tamgshixing@smu.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33011520

Citation

Li, Linghua, et al. "Molecular and Serological Characterization of SARS-CoV-2 Infection Among COVID-19 Patients." Virology, vol. 551, 2020, pp. 26-35.
Li L, Liang Y, Hu F, et al. Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients. Virology. 2020;551:26-35.
Li, L., Liang, Y., Hu, F., Yan, H., Li, Y., Xie, Z., Huang, L., Zhao, J., Wan, Z., Wang, H., Shui, J., Cai, W., & Tang, S. (2020). Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients. Virology, 551, 26-35. https://doi.org/10.1016/j.virol.2020.09.008
Li L, et al. Molecular and Serological Characterization of SARS-CoV-2 Infection Among COVID-19 Patients. Virology. 2020;551:26-35. PubMed PMID: 33011520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients. AU - Li,Linghua, AU - Liang,Yuanhao, AU - Hu,Fengyu, AU - Yan,Huanchang, AU - Li,Yueping, AU - Xie,Zhiwei, AU - Huang,Liping, AU - Zhao,Jianhui, AU - Wan,Zhengwei, AU - Wang,Haiying, AU - Shui,Jingwei, AU - Cai,Weiping, AU - Tang,Shixing, Y1 - 2020/09/28/ PY - 2020/06/16/received PY - 2020/09/23/revised PY - 2020/09/23/accepted PY - 2020/10/5/pubmed PY - 2020/12/15/medline PY - 2020/10/4/entrez KW - Anti-SARS-CoV-2 antibodies KW - COVID-19 KW - SARS-CoV-2 KW - Viral RNA SP - 26 EP - 35 JF - Virology JO - Virology VL - 551 N2 - BACKGROUND: SARS-CoV-2 is a novel coronavirus and the cause of COVID-19. More than 80% of COVID-19 patients exhibit mild or moderate symptoms. In this study, we investigated the dynamics of viral load and antibodies against SARS-CoV-2 in a longitudinal cohort of COVID-19 patients with severe and mild/moderate diseases. METHODS: Demographic and clinical information were obtained. Serial samples of blood, nasal and pharyngeal and anal swabs were collected at different time points post-onset. SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies were measured by qRT-PCR and immunoassays, respectively. RESULTS: Respiratory SARS-CoV-2 RNA was detectable in 58.0% (58/100) COVID-19 patients upon admission and lasted for a median of 13 days post-onset. In addition, 5.9% (1/17) and 20.2% (19/94) of the blood and anal swab specimens were positive for SARS-CoV-2 RNA, respectively. Anal viral RNA was more frequently detected in the patients who were positive for viral RNA in the respiratory samples upon admission. Specific anti-SARS-CoV-2 antibody developed within two weeks after onset, reached peak approximately 17 days post-onset and then maintained at relatively high level up to 50 days we analyzed in most patients. However, the levels of antibodies were variable among the patients. High titers of antibodies appeared to be associated with the severity of the disease. Furthermore, viral proteins from different sources showed significant difference of serological sensitivity especially during the first week post-onset. CONCLUSIONS: Our results indicate rapid clearance or self-elimination of viral RNA in about half of the COVID-19 patients upon admission. Viral RNA shedding of SARS-CoV-2 occurred in multiple tissues including the respiratory system, blood, and intestine. Variable levels of specific anti-SARS-CoV-2 antibody may be associated with disease severity. These findings have shed light on viral kinetics and antibody response in COVID-19 patients and provide scientific evidence for infection control and patient management. SN - 1096-0341 UR - https://www.unboundmedicine.com/medline/citation/33011520/Molecular_and_serological_characterization_of_SARS_CoV_2_infection_among_COVID_19_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0042-6822(20)30192-6 DB - PRIME DP - Unbound Medicine ER -